chloromethyl (8S,9S,10R,13S,14S)-2-hydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-17-carboxylate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: chloromethyl (8S,9S,10R,13S,14S)-2-hydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-17-carboxylate
• 化学式: C₂₁H₂₉ClO₄
• 分子量: 380.9
• InChiKey: MRFHDQJVIBTSMV-ZVQSWIPMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT
  申请人：Kala Pharmaceuticals, Inc.

  公开号：EP2844223A1

  公开（公告）日：2015-03-11
• [EN] PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT<br/>[FR] NANOPARTICULES PHARMACEUTIQUES À TRANSPORT MUCOSAL AMÉLIORÉ
  申请人：KALA PHARMACEUTICALS INC

  公开号：WO2013166436A1

  公开（公告）日：2013-11-07

  Particles, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. The pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.